Exelixis (EXEL) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Exelixis (NASDAQ: EXEL) in the last few weeks:

• 10/19/2026 – Exelixis had its “market outperform” rating reaffirmed by Citigroup Inc..
• 10/19/2026 – Exelixis had its price target raised by Citizens Jmp from $55.00 to $65.00. They now have a “market outperform” rating on the stock.
• 10/9/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $45.00 to $51.00. They now have a “sector perform” rating on the stock.
• 10/8/2026 – Exelixis was upgraded by Weiss Ratings from “buy (a-)” to “buy (a)”.
• 10/8/2026 – Exelixis had its price target lowered by Royal Bank Of Canada from $46.00 to $45.00. They now have a “sector perform” rating on the stock.
• 10/7/2026 – Exelixis had its price target raised by Truist Financial Corporation from $52.00 to $54.00. They now have a “hold” rating on the stock.
• 9/14/2026 – Exelixis had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/11/2026 – Exelixis had its “outperform” rating reaffirmed by William Blair.
• 9/1/2026 – Exelixis was upgraded by Zacks Research from “strong sell” to “hold”.

Insider Activity

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of Exelixis stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares in the company, valued at $862,799.14. The trade was a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.60% of the company’s stock.

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.